Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fuchs, M.
Right arrow Articles by Drexler, H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fuchs, M.
Right arrow Articles by Drexler, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Pharmacotherapy of chronic heart failure: current status and future aspects

M. Fuchs and H. Drexler*

Medizinische Hochschule Hannover, Hannover, Germany

* Correspondence: Helmut Drexler MD, Medizinische Hochschule Hannover, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany.

Abstract

Chronic heart failure is among the main causes of death in Western countries. Despite state of the art treatments, including angiotensin-converting enzyme inhibitors, beta-blockers and spironolactone, survival and relief from symptoms are still unacceptably poor in patients with chronic heart failure. The present article provides an overview of the current status in treatment of heart failure and points out possible treatment options in the future. It appears possible to reduce or at least delay progression of heart failure by adding drugs that interfere with novel pathophysiological aspects of the disease (e.g. those that activate the neuroendocrine system and cytokines, alter calcium homeostasis and energy depletion, and prevent hypertrophy) as well as by targeting oxidative stress and stimulating cardiac regeneration by stem cells.

Key Words: Chronic heart failure • therapy • neuroendocrine system • cytokines • calcium • regeneration • NO

References

  1. Pitt B, Zannad F, Remme WJ, Cody R, et al. Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–717[Abstract/Free Full Text]
  2. Sutsch G, Kiowski W. Endothelin and endothelin receptor antagonism in heart failure. J Cardiovasc Pharmacol. 2000;35(suppl 2):S69–S73[CrossRef][Web of Science][Medline]
  3. Kalra P, Moon J, Coats A. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol. 2002;85:195[CrossRef][Web of Science][Medline]
  4. Packer M, Coats AJ, Fowler MB, et al. Effect of carvediolo on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–1658[Abstract/Free Full Text]
  5. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675[Abstract/Free Full Text]
  6. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet. 1997;349:375–380[CrossRef][Web of Science][Medline]
  7. Drexler H, Coats AJ. Explaining fatigue in congestive heart failure. Annu Rev Med. 1996;47:241–256[CrossRef][Web of Science][Medline]
  8. Jin H, Yang R, Awad TA, et al. Effects of early angiotensin-converting enzyme inhibition on cardiac gene expression after acute myocardial infarction. Circulation. 2001;103:736–742[Abstract/Free Full Text]
  9. Tsutamoto T, Hisanaga T, Wada A, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol. 1998;31:391–398[Abstract/Free Full Text]
  10. Wollert KC, Drexler H. The role of interleukin-6 in the failing heart. Heart Fail Rev. 2001;6:95–103[CrossRef][Medline]
  11. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 1992;257:387–389[Abstract/Free Full Text]
  12. Hirota H, Yoshida K, Kishimoto T, Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci USA. 1995. p. 4862–4866
  13. Gwechenberger M, Mendoza LH, Youker KA, et al. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation. 1999;99:546–551[Abstract/Free Full Text]
  14. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation. 1998;98:149–156[Abstract/Free Full Text]
  15. Yamauchi-Takihara K, Ihara Y, Ogata A, Yoshizaki K, Azuma J, Kishimoto T. Hypoxic stress induces cardiac myocyte-derived interleukin-6. Circulation. 1995;91:1520–1524[Abstract/Free Full Text]
  16. Yue P, Massie BM, Simpson PC, Long CS. Cytokine expression increases in nonmyocytes from rats with postinfarction heart failure. Am J Physiol. 1998;275:H250–H258
  17. Negoro S, Kunisada K, Tone E, et al. Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction. Cardiovasc Res. 2000;47:797–805[Abstract/Free Full Text]
  18. Hirota H, Chen J, Betz UA, et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell. 1999;97:189–198[CrossRef][Web of Science][Medline]
  19. Podewski EK, Hilfiker-Kleiner D, Hilfiker A, et al. Decreased activation of the JAK2-STAT3 signaling pathwa in patients with end-stage dilated cardiomyopathy. Eur Heart J. 2002;4:501
  20. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8:459–465[CrossRef][Web of Science][Medline]
  21. Wettschureck N, Rütten H, Zywietz A, et al. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of in cardiomyocytes. Nat Med. 2001;7:1236–1240[CrossRef][Web of Science][Medline]
  22. Asakura M, Kitakaze M, Takashima S, et al. Cardiac hypertrophy is inhibited by antagonism of ADAM 12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med. 2002;8:35–40[CrossRef][Web of Science][Medline]
  23. Harada K, Komuro I, Shiojima I, et al. Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation. 1998;97:1952–1959[Abstract/Free Full Text]
  24. Fiedler B, Lohmann SM, Smolenski A, et al. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. proc Natl Acad Sci USA. 2002. p. 11363–11368
  25. Scherrer-Crosbie M, Ullrich R, Bloch KD, et al. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation. 2001;104:1286–1291[Abstract/Free Full Text]
  26. Li Y, Huang TT, Carlson EJ, et al. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet. 1995;11:376–381[CrossRef][Web of Science][Medline]
  27. Melov S, Ravenscroft J, Malik S, et al. Extension of life-span with superoxide dismutase/catalase mimetics. Science. 2000;289:1567–1569[Abstract/Free Full Text]
  28. Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001;108:1429–1437[CrossRef][Web of Science][Medline]
  29. Hasenfuss G, Reinecke H, Studer R, et al. Calcium cycling proteins and force-frequency relationship in heart failure. Basic Res Cardiol. 1996;9(suppl 2):17–22[CrossRef]
  30. Miyamoto MI, del Monte F, Schmidt U, et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci USA. 2000. p. 793–798
  31. del Monte F, Harding SE, Schmidt U, et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation. 1999;100:2308–2311[Abstract/Free Full Text]
  32. Frank K, Kranias EG. Phospholamban and cardiac contractility. Ann Med. 2000;32:572–578[Web of Science][Medline]
  33. Minamisawa S, Hoshijima M, Chu G, et al. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell. 1999;99:313–322[CrossRef][Web of Science][Medline]
  34. Menasche P, Hagege AA, Scorsin M, et al. Myoblast transplantation for heart failure. Lancet. 2001;357:279–280[CrossRef][Web of Science][Medline]
  35. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410:701–705[CrossRef][Medline]
  36. Strauer BE, Brehm M, Zeus T, et al. Intracoronary, human autologous stem cell transplantation for myocardial regeneration following myocardial infarction. Dtsch Med Wochenschr. 2001;126:932–938[CrossRef][Medline]
  37. Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA. 2001. p. 10344–10349

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fuchs, M.
Right arrow Articles by Drexler, H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fuchs, M.
Right arrow Articles by Drexler, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?